ReviewDiagnostics (Basel, Switzerland)2023
Liquid Biopsy in the Management of Breast Cancer Patients: Where Are We Now and Where Are We Going.
Review in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 50 citations in OpenAlex.
- Non-Invasive Diagnosis of Early Breast Cancer: Current and Emerging Liquid Biopsy Biomarkers.Cancers · 2026Review
- Next-generation sequencing using a targeted gene panel in advanced solid tumors: five years of experience from an Italian referral institution.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- USP44, ZNF454, and GPRC5B ctDNA Methylation Markers in Breast Cancer: Limited Clinical Relevance for Disease Monitoring and Tumor Characteristics.Asia-Pacific journal of clinical oncology · 2026Article
- Analytical and clinical validation of a novel CE-IVD kit forThe journal of liquid biopsy · 2026Article
- Scrutinizing the potential role of non-coding RNAs as biomarkers in Egyptian females with early and metastatic breast cancer.BMC cancer · 2026Article
- Circulating Plasma Circular RNAs hsa_circ_0001785 and hsa_circ_0079876 as Promising Noninvasive Diagnostic Biomarkers for Breast Cancer: A Case-Control Study.The breast journal · 2026Article
- Liquid Biopsy and Multi-Omic Biomarkers in Breast Cancer: Innovations in Early Detection, Therapy Guidance, and Disease Monitoring.Biomedicines · 2025Review
- Minimal Residual Disease in Breast Cancer: Tumour Microenvironment Interactions, Detection Methods and Therapeutic Approaches.International journal of molecular sciences · 2025Review
- Integrating Molecular Phenotyping into Treatment Algorithms for Advanced Oestrogen Receptor-Positive Breast Cancer.Cancers · 2025Review
- Longitudinal profiling of hormone receptor positive, HER2 negative metastatic breast cancer through droplet digital PCR-based circulating tumor DNA fragmentomics.Translational oncology · 2025Article
- Harmonization trial onThe journal of liquid biopsy · 2025Article
- The impact of liquid biopsy in breast cancer: Redefining the landscape of non-invasive precision oncology.The journal of liquid biopsy · 2025Review
- Multidisciplinary discussion on phenotypical characterization of metastatic breast cancer and patient pathway optimization from an expert panel across South Italian regions.Scientific reports · 2025Article
- Liquid biopsy in gynecological cancers: a translational framework from molecular insights to precision oncology and clinical practice.Journal of experimental & clinical cancer research : CR · 2025Review
- Enabling sensitive and precise detection of ctDNA through somatic copy number aberrations in breast cancer.NPJ breast cancer · 2025Article
- Psychological Considerations Associated with Lobular Breast Cancer.Current psychiatry reports · 2025Review
- Circulating Cell-Free DNA Integrity for Breast and Prostate Cancer: What Is the Landscape for Clinical Management of the Most Common Cancers in Women and Men?International journal of molecular sciences · 2025Review
- Comprehensive review of male breast cancer: Understanding a rare condition.Oncology research · 2025Review
- Cytokine levels in breast cancer are highly dependent on cytomegalovirus (CMV) status.Breast cancer research and treatment · 2024Article
- Circulating tumor cells in breast cancer: clinical validity and utility.NPJ breast cancer · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liquid biopsy (LB) is an emerging diagnostic tool that analyzes biomarkers in the blood (and possibly in other body fluids) to provide information about tumor genetics and response to therapy. This review article provides an overview of LB applications in human cancer with a focus on breast cancer patients. LB methods include circulating tumor cells and cell-free tumor products, such as circulating tumor DNA. LB has shown potential in detecting cancer at an early stage, monitoring tumor progression and recurrence, and predicting patient response to therapy. Several studies have demonstrated its clinical utility in breast cancer patients. However, there are limitations to LB, including the lack of standardized assays and the need for further validation. Future potential applications of LB include identifying the minimal residual disease, early detection of recurrence, and monitoring treatment response in various cancer types. LB represents a promising non-invasive diagnostic tool with potential applications in breast cancer diagnosis, treatment, and management. Further research is necessary to fully understand its clinical utility and overcome its current limitations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.